Use of Novel Oral Anticoagulants Post-cardioversion in Atrial Fibrillation: A Safety Review.
Loading...
Date
2015
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Atrial fibrillation is considered the most common sustained arrhythmia worldwide, especially in
geriatric population and is associated with significant morbidity and mortality. Arterial embolization
is the most serious complication of atrial fibrillation. Vitamin K antagonists were the only form of
oral anticoagulant medication approved for long-term use since 1940s, till the advent of three novel
oral anticoagulants- dabigatran, rivaroxaban and apixaban. The new anticoagulants are more
convenient to administer than warfarin. Pivotal trials of these drugs showed that they are not only
as effective as warfarin, but also cause less intracranial bleeding. There is data emerging
regarding the safety of these agents in the context of cardioversion. The purpose of this review is
to examine the current published safety data for the use of novel oral anticoagulants around the
time of cardioversion.
Description
Keywords
New oral anticoagulants, non-valvular atrial fibrillation, genetic, polymorphism, mutations, cardioversion, echocardiogram, transesophageal, thromboembolic, intracranial, bleeding
Citation
Mehra S, Prodduturvar P, Marcu Constantin B, Chelu Mihail G. Use of Novel Oral Anticoagulants Post-cardioversion in Atrial Fibrillation: A Safety Review. British Journal of Medicine and Medical Research. 2015; 7(9): 718-722.